Pegylated protein encapsulated multivesicular liposomes: A novel approach for sustained release of interferon α

Drug Development and Industrial Pharmacy

Volumn 32, Issue 6, 2006, Pages 699-707

  Vyas, S P ^a   Rawat, M ^a   Rawat, A ^a   Mahor, S ^a   Gupta, P N ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Interferon ; Multivesicular liposomes; Pegylated protein encapsulation technology; Pegylation; Sustained release

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; CHLOROFORM; ETHER; LIPOSOME; MACROGOL; ORGANIC SOLVENT;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; DRUG SYNTHESIS; EMULSION; ENCAPSULATION; EVAPORATION; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; SUSTAINED DRUG RELEASE;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; CYTOPATHOGENIC EFFECT, VIRAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG STABILITY; HUMANS; INTERFERON ALFA-2A; LIPOSOMES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; VESICULAR STOMATITIS INDIANA VIRUS; VESICULAR STOMATITIS-INDIANA VIRUS;

EID: 33746810003     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500528954     Document Type: Article

References (23)

1. Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W. J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z. X., Modi, M. W., Farid, A., & Berthold, W. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjugate Chem., 12, 195-202.
2. Delgado, C., Francis, G. E., & Fisher, D. (1992) The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst., 9, 249-304.
3. Diwan, M., Park, T. G. (2001) Pegylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Rel., 73, 233-244.
4. Diwan, M., & Park, T. G. (2003) Stabilization of recombinant interferon-α by pegylation for encapsulation in PLGA microspheres. Int. J. Pharm., 252, 111-122.
5. Ellena, J. F., Le, M., Cafiso, D. S., Solis, R. M., Langston, M., & Sankaram, M. B. Distribution of phospholipids and triglycerides in multivesicular lipid particles. Drug Deliv., 6, 97-106.
6. Eppstein, D. A., & Stewart, W. E. (1981) 2nd Binding and capture of human interferon-alpha by reverse evaporation vesicles, multilamellar vesicles, and small unilamellar vesicles. J. Interferon Res., 1, 495-504.
7. Glue, P., Rouzier-Panis, R., Raffanel, C., Sabo, R., Gupta, S. K., Salfi, M., Jacobs, S., & Clement, R. P. (2000) A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology, 32, 647-653.
8. Gregoriadis, G. (1991) Overview of liposomes. J. Antimicrob. Chemother., 28, 39-48.
9. Johansen, P., Men, Y., Audran, R., Corradin, G., Merkle, H. P., & Gander, B. (1998) Improving stability and release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives. Pharma. Res., 15, 1103-1110.
10. Katre, N. V., Asherman, J., Schaefer, H., & Hora, M. (1998) Multivesicular liposome (DepoFoam® ) technology for the sustained delivery of insulin-like growth factor-I (IGF-I). J. Pharm. Sci., 87, 1341-1346.
11. Katre, N. V. (1990) Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. J. Immunol., 144, 209-213.
12. Katre, N. V. (1993) The conjugation of proteins with polyethylene glycol and other polymers: altering properties of proteins to enhance their therapeutic potential. Adv. Drug Del. Rev., 10, 91-114.
13. Kim, S., Turker, M. S., Chi, E. Y., Sela, S., & Martin, G. M. (1983) Preparation of multivesicular liposomes. Biochim. Biophys. Acta, 728, 339-348.
14. Langston, M. V., Ramprasad, M. P., Kararli, T. T., Galluppi, G. R., & Katre N. V. (2003) Modulation of the sustained delivery of myelopoietin (Leridistim) encapsulated in multivesicular liposomes (DepoFoam). J. Control. Rel., 89, 87-99.
15. Liang, T. J., Rehermann, B., Seeft, L. B., Hoofnagle, J. H. (2000) Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann. Int. Med., 132, 296-305.
16. Maghraby, G. M., Williams, A. C., & Barry, B. W. (1999) Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J. Pharm. Pharmacol., 51, 1123-34.
17. Mantripragada, S. (2002) A lipid based depot (Depofoam® Technology) for sustained release drug delivery. Prog. Lipid Res., 41, 392-406.
18. New, R. R. C. (1990) Liposomes: A practical approach New, R.R.C. Ed. New York: Oxford University Press: 33-104.
19. Bailon, P., & Berthold, W. (1998) Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today, 1, 352-356.
20. Rubinstein, S., Familletti, P., & Pestka, S. (1981) Convenient assay for interferons. J. Virol., 37, 755-758.
21. Vyas, S. P., Khar, R. K. (2001) Targeted and controlled drug delivery. New Delhi: CBS Publisher and Distributor.
22. Ye, Q., Asherman, J., Stevenson, M., Brownson, E., & Katre, N. V. (2000) DepoFoam® technology: a vehicle for controlled delivery of protein and peptide drugs. J. Control. Rel., 64, 155-166.
23. Zalipsky, S., & Harris, J. M. (1997) Introduction to chemistry and biological applications of poly(ethylene) glycol. In Harris, J. M., & Zalipsky, S. Eds. Poly(ethylene) glycol chemistry and biological applications. Washington DC: American Chemical Society 1-13.